Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved RILUTEK op - vejer risiciene til forlængelse af overlevelsen eller af tiden, indtil mekanisk ventilation er nødvendig, for patienter med amyotrofisk lateral sklerose.
The Committee for Medicinal products for Human Use (CHMP) decided that RILUTEK’ s benefits are greater than its risks to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis.